These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 38375066)

  • 1. Emerging therapies for MASLD and their impact on plasma lipids.
    Nguyen M; Asgharpour A; Dixon DL; Sanyal AJ; Mehta A
    Am J Prev Cardiol; 2024 Mar; 17():100638. PubMed ID: 38375066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
    Burmeister Y; Weyer K; Dörre A; Seilheimer B
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
    Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
    Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review regarding the article 'Electrocardiographic abnormalities in patients with metabolic dysfunction-associated Steatotic liver disease: A systematic review and meta-analysis.'.
    Li C; Wang T; Song J
    Curr Probl Cardiol; 2024 Jul; 49(7):102626. PubMed ID: 38718937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic dysfunction-associated steatotic liver disease and the heart.
    Driessen S; Francque SM; Anker SD; Castro Cabezas M; Grobbee DE; Tushuizen ME; Holleboom AG
    Hepatology; 2023 Dec; ():. PubMed ID: 38147315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.
    Kjærgaard K; Daugaard Mikkelsen AC; Landau AM; Eriksen PL; Hamilton-Dutoit S; Magnusson NE; Thomsen MB; Chen F; Vilstrup H; Mookerjee RP; Bay-Richter C; Thomsen KL
    JHEP Rep; 2024 Mar; 6(3):100992. PubMed ID: 38415019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
    Takahashi Y; Dungubat E; Kusano H; Fukusato T
    Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin.
    Meroni M; Longo M; Dongiovanni P
    Front Endocrinol (Lausanne); 2024; 15():1411706. PubMed ID: 38846491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic dysfunction-associated steatotic liver disease and atherosclerosis.
    Castillo-Núñez Y; Almeda-Valdes P; González-Gálvez G; Arechavaleta-Granell MDR
    Curr Diab Rep; 2024 Jul; 24(7):158-166. PubMed ID: 38700793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pathophysiology of MASLD: an immunometabolic perspective.
    Schwärzler J; Grabherr F; Grander C; Adolph TE; Tilg H
    Expert Rev Clin Immunol; 2024 Apr; 20(4):375-386. PubMed ID: 38149354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Shin S; Kim J; Lee JY; Kim J; Oh CM
    J Obes Metab Syndr; 2023 Dec; 32(4):289-302. PubMed ID: 38049180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between metabolic dysfunction-associated steatotic liver disease, cardiovascular and cerebrovascular diseases and the thickness of carotid plaque.
    Huang Y; Wang Y; Xiao Z; Yao S; Tang Y; Zhou L; Wang Q; Xie Y; Zhang L; Zhou Y; Lu Y; Zhu W; Chen M
    BMC Cardiovasc Disord; 2023 Nov; 23(1):554. PubMed ID: 37951879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.
    Abushamat LA; Shah PA; Eckel RH; Harrison SA; Barb D
    Clin Gastroenterol Hepatol; 2024 Feb; ():. PubMed ID: 38367743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic signatures of metabolic dysfunction-associated steatotic liver disease in severely obese patients.
    Babu AF; Palomurto S; Kärjä V; Käkelä P; Lehtonen M; Hanhineva K; Pihlajamäki J; Männistö V
    Dig Liver Dis; 2024 Jun; ():. PubMed ID: 38825414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and Risk Factors of MASLD and Liver Fibrosis amongst the Penitentiary Population in Catalonia: The PRISONAFLD Study.
    Rivera-Esteban J; Jiménez-Masip A; Muñoz-Martínez S; Augustin S; Guerrero RA; Gabriel-Medina P; Ferrer-Costa R; Rodríguez-Frías F; Turu E; Marco A; Pericàs JM; On Behalf Of The Prisonafld Study Group Collaborators
    J Clin Med; 2023 Nov; 12(23):. PubMed ID: 38068330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma.
    Rivera-Esteban J; Muñoz-Martínez S; Higuera M; Sena E; Bermúdez-Ramos M; Bañares J; Martínez-Gomez M; Cusidó MS; Jiménez-Masip A; Francque SM; Tacke F; Minguez B; Pericàs JM
    Clin Gastroenterol Hepatol; 2024 Apr; ():. PubMed ID: 38604295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes.
    Godoy-Matos AF; Valério CM; Silva Júnior WS; de Araujo-Neto JM; Bertoluci MC
    Diabetol Metab Syndr; 2024 Jan; 16(1):23. PubMed ID: 38238868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease.
    Armandi A; Bugianesi E
    Eur J Intern Med; 2024 Apr; 122():20-27. PubMed ID: 38262842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.